Shares of Hospira Inc. lost 7 percent of their value after the company said fourth-quarter profits fell nearly 40 percent, as the maker of drugs and devices works to improve product quality in the wake of regulatory issues.
Hospira had lower-than-anticipated fourth quarter sales because it has been unable to deliver products to customers fast enough due largely to “quality enhancement initiatives.” Get the full story »
